# reload+after+2024-01-23 16:44:20.856820
address1§177-181 Avenue Pierre Brossolette
city§Montrouge
zip§92120
country§France
phone§33 1 55 42 78 78
fax§33 1 43 26 10 83
website§https://www.dbv-technologies.com
industry§Biotechnology
sector§Healthcare
longBusinessSummary§DBV Technologies S.A., a clinical-stage biopharmaceutical company, engages in the research and development of epicutaneous immunotherapy products. Its lead product candidate is Viaskin Peanut, an immunotherapy product, which has completed Phase III clinical trial for the treatment of peanut allergies. The company is also developing Viaskin Milk that is in Phase I/II clinical trial for the treatment of immunoglobulin E (IgE) mediated cow's milk protein allergy (CMPA) and eosinophilic esophagitis. Its other earlier stage research programs include a vaccine for the respiratory syncytial virus, as well as treatments for Crohn's disease, celiac disease, and type I diabetes. The company has a collaboration with Nestlé Health Science to develop MAG1C, a ready-to-use atopy patch test for the diagnosis of non-IgE mediated CMPA in infants and toddlers. DBV Technologies S.A. was incorporated in 2002 and is headquartered in Montrouge, France.
fullTimeEmployees§97
companyOfficers§[{'maxAge': 1, 'name': 'Mr. Daniel  Tassé', 'age': 63, 'title': 'CEO & Director', 'yearBorn': 1960, 'fiscalYear': 2022, 'totalPay': 1213805, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Dr. Pharis  Mohideen', 'age': 58, 'title': 'Chief Medical Officer', 'yearBorn': 1965, 'fiscalYear': 2022, 'totalPay': 725120, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Ms. Virginie Simone Jeanine Verrechia Boucinha M.B.A.', 'age': 53, 'title': 'CFO & Principal Accounting Officer', 'yearBorn': 1970, 'fiscalYear': 2022, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Mr. Pascal  Wotling', 'title': 'Chief Technical Operations Officer & Chief Quality Officer', 'fiscalYear': 2022, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Ms. Michele F. Robertson', 'title': 'Chief Legal Officer', 'fiscalYear': 2022, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Ms. Caroline  Daniere', 'age': 48, 'title': 'Chief Human Resources Officer & Chief of Staff', 'yearBorn': 1975, 'fiscalYear': 2022, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Dr. Wence  Agbotounou', 'title': 'Chief Clinical Trial Officer & Senior VP', 'fiscalYear': 2022, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Mr. Edward P. Jordan M.B.A.', 'age': 55, 'title': 'Senior Vice President of Commercial Operations North America', 'yearBorn': 1968, 'fiscalYear': 2022, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Alan  Kerr', 'title': 'Senior VP & Head of Global Regulatory Affairs', 'fiscalYear': 2022, 'exercisedValue': 0, 'unexercisedValue': 0}]
auditRisk§6
boardRisk§9
compensationRisk§10
shareHolderRightsRisk§1
overallRisk§10
governanceEpochDate§1704067200
compensationAsOfEpochDate§1672444800
maxAge§86400
priceHint§4
payoutRatio§0.0
beta§0.845
priceToSalesTrailing12Months§33.71046
currency§USD
dateShortInterest§1702598400
forwardEps§-0.81
pegRatio§-0.05
exchange§NMS
quoteType§EQUITY
shortName§DBV Technologies S.A.
longName§DBV Technologies S.A.
firstTradeDateEpochUtc§1413984600
timeZoneFullName§America/New_York
timeZoneShortName§EST
uuid§743365e9-cced-3e92-b167-5177b9f2dfd9
gmtOffSetMilliseconds§-18000000
targetHighPrice§10.04
targetLowPrice§1.01
targetMeanPrice§5.02
targetMedianPrice§4.01
recommendationMean§2.7
recommendationKey§hold
numberOfAnalystOpinions§3
quickRatio§5.282
grossMargins§1.0
ebitdaMargins§0.0
trailingPegRatio§None
